December 21, 2020 -- Q2 Solutions has announced a partnership with Adaptive Biotechnologies to use Adaptive's products in its clinical trial laboratory services.
Q2 will offer clinical trial services with Adaptive's immunoSEQ Assay and immunoSEQ T-mAP COVID. ImmunoSEQ Assay is a next-generation sequencing immunosequencing tool designed to quantify adaptive immune receptors at high throughput, while immunoSEQ T-mAP COVID is a proprietary research and data analysis product for assessing T-cell immune response for vaccines being developed.
Q2 will use Adaptive's proprietary bioinformatics pipeline to perform testing and data analysis and run studies directly for pharmaceutical and biotechnology clients. It is the first large, global organization offering laboratory services to enter into a partnership with Adaptive and provide the two clinical trial solutions, according to Q2.
The partnership will expand Q2’s global immuno-oncology and COVID-19 testing portfolio, the company noted. Terms of the partnership were not disclosed.